Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
mRNA Manufacturing
Sort By
Newest First
1 / 1
1 / 1
mRNA Innovations
Technology Advances Needed to Drive Future mRNA Growth
Hagen Richter, Ph.D.
PAO-04-24-CL-04
Apr 15, 2024
mRNA Manufacturing
Navigating mRNA Manufacturing with Flexibility and Innovation
Michael van der Horst, Ph.D.
PAO-04-24-CL-02
Apr 08, 2024
New Integrated mRNA Offering
Building on Experience and Investing in an Integrated mRNA Offering
Jessica Madigan; Normand Blais
BIOVECTRA
PAO-07-23-CL-03
Jul 31, 2023
Risk Management in mRNA Manufacture
Managing Risk in Cutting-Edge mRNA Therapeutics
Jessica Madigan; Normand Blais
BIOVECTRA
PAO-07-23-CL-04
Jul 31, 2023
mRNA Ultra-Cold Chain Management
Ultra-Cold Chain and Supply Chain Management Strategies for mRNA
Eunseo (Ency) Lee, Ph.D; Jungkeun (Henry) Oh; Hanel Hwang
Samsung Biologics
PAO-02-23-CL-09
Mar 09, 2023
mRNA Manufacturing
Investing in the Future of mRNA Manufacturing
Esther Yoo, Ph.D.
Samsung Biologics
PAO-11-022-CL-02
Nov 16, 2022
Quality in mRNA Manufacturing
Quality in Equals Quality Out in mRNA Manufacturing
Judith McCorry
Vernal Biosciences
PAO-10-022-CL-08
Nov 08, 2022
mRNA Manufacture
Platform Processes and End-to-End Capabilities Position Vernal Biosciences as a Critical CDMO Resource for mRNA Developers
Tonia Becker
Nice Insight
PAO-10-022-CL-03
Oct 25, 2022
mRNA Manufacturing
Overcoming Bottlenecks in mRNA Manufacturing
Pierre Catignol; Huisub Lim
Samsung Biologics
PAO-10-022-CL-04
Oct 24, 2022
mRNA
Limitless Potential of mRNA Creates Tremendous Excitement Despite Uncertainties
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-10-022-NI-02
Oct 11, 2022
Column: M&A
Who's Left to Acquire in CDMO Biomanufacturing? A Select Few.
Nigel Walker
Nice Insight
PAO-06-022--NI-12
Jun 24, 2022
mRNA Manufacturing
Vernal Biosciences Raises $21 Million to Accelerate mRNA Manufacturing Growth
Vernal Biosciences
PR-M06-22-01-351
Jun 02, 2022
Column: Technology
mRNA Technology: Is the Long Path Behind Leading to Endless Successes Ahead?
Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.; Danielle Alvarez
Pharma's Almanac
PAO-03-022-NI-02
Mar 23, 2022
mRNA
Leveraging Existing Technologies with New Dedicated Facilities for mRNA Projects
Scott Doncaster; Marc Sauer, Ph.D.
BIOVECTRA
PAO-02-022-CL-07
Mar 12, 2022
Facility Acquisition
MilliporeSigma Announces Closing of Exelead Acquisition and Plans to Invest More Than € 500 Million in Technology Scale-Up
MilliporeSigma
PR-M02-22-20
Feb 23, 2022
CDMO Acquisition
Recipharm Acquires Arranta Bio, a CDMO Leader in Advanced Therapy Medicinal Products (ATMPs), to Expand its Biologics Offering in the U.S.
Recipharm AB
PR-M02-22-17
Feb 18, 2022
mRNA Vaccine Manufacturing
Presenting an Integrated Solution for mRNA Vaccine Manufacturing
Mark Bamforth; Dave Stevens
Arranta Bio
PAO-01-22-R250-04
Jan 26, 2022
mRNA Manufacturing
Serving an Accelerated Market with mRNA Production
Mark Bamforth
Arranta Bio
PAO-11-21-CL-06
Dec 08, 2021
Investing in mRNA Production
Michael Wourms
Arranta Bio
PA766
Nov 22, 2021
mRNA Manufacturing
Limiting Risk In mRNA Development and Production
Doug Kennedy
Arranta Bio
PAO-11-21-CL-05
Nov 22, 2021
